Medicine accessibility in South Africa remains a pressing public health concern, especially in a country burdened by a dual healthcare system and high rates of infectious and non-communicable diseases. While policy efforts have been made to enhance access, systemic inefficiencies, regulatory delays, and economic disparities continue to limit equitable availability of essential medicines. This article examines the factors affecting medicine accessibility in South Africa and proposes data-informed interventions to address these challenges.
- The Public vs. Private Sector Divide
South Africa’s healthcare landscape is marked by a sharp divide between the public and private sectors. Approximately 84% of the population relies on the public healthcare system, which is chronically under-resourced and plagued by stockouts of essential medicines [1]. In contrast, the private sector serves just 16% of the population but consumes a disproportionately large share of healthcare expenditure, offering greater access to a wider range of medicines.
The unequal distribution of resources exacerbates medicine inaccessibility, particularly for rural and low-income populations. Despite efforts such as the introduction of the National Essential Medicines List (EML), implementation gaps, logistics inefficiencies, and procurement challenges have undermined the effectiveness of these policies [2].
- Regulatory Delays and Market Entry Barriers
The approval and registration of medicines through the South African Health Products Regulatory Authority (SAHPRA) has historically been a bottleneck. A significant backlog, inherited from the former Medicines Control Council, once delayed drug registrations for up to five years [3]. Although SAHPRA has made strides in clearing the backlog and improving timelines through its Backlog Clearance Project, the pace of new generic and innovative medicine introductions remains slower than desired.
Moreover, delays in the approval of World Health Organization (WHO)-prequalified medicines—which are already vetted for safety and efficacy—further hinder timely access to essential treatments, especially for diseases like tuberculosis and HIV/AIDS [4].
- Pricing Pressures and Affordability Challenges
Medicine pricing in South Africa is governed by the Single Exit Price (SEP) policy, introduced in 2004 to prevent excessive markups and enhance transparency. While SEP has controlled price inflation, it has also led to pricing rigidity, making it difficult to adjust for market shifts or introduce lower-cost alternatives [5]. High prices in the private sector often push patients to resort to out-of-pocket payments or forego treatment entirely.
- Supply Chain Disruptions and Stockouts
Frequent stockouts of essential medicines in public hospitals and clinics remain a persistent problem. A 2021 report by the Stop Stockouts Project found that over 30% of surveyed health facilities had experienced stockouts in the past three months [6]. These stockouts are driven by supply chain inefficiencies, poor forecasting, and procurement delays. Another key contributor to medicine shortages in the public sector is the delay or non-payment to suppliers, which places financial strain on these providers and disrupts the continuity of supply.
In rural areas, limited infrastructure and transportation challenges exacerbate stock availability issues, undermining trust in the public health system and forcing patients to seek costly alternatives in the private sector.
- Policy and Innovation Pathways
Efforts to improve medicine accessibility in South Africa include a range of policy and operational innovations. For example, digital health tools, such as electronic inventory management systems and mobile prescription apps, have been piloted to improve transparency and real-time tracking of medicine stock levels.
Additionally, some health system stakeholders advocate for greater use of collaborative procurement mechanisms and regional harmonization with neighbouring countries. These strategies could help address inefficiencies in supply chain logistics and reduce the cost burden on the national system.
Conclusion
Improving medicine accessibility in South Africa requires a multi-pronged approach: accelerating regulatory approvals, addressing supply chain inefficiencies, strengthening public-sector logistics and financial management and ensuring equitable allocation of resources across the healthcare system. These efforts must be supported by transparent governance, capacity building, and constructive collaboration between government, private sector, and civil society.
As South Africa continues to address the challenges within its healthcare system, ensuring consistent and equitable access to essential medicines will remain a central pillar of its public health strategy.
References
- World Health Organization (2021). South Africa Health System Review.
- Gray, A., & Suleman, F. (2015). Implementing the Essential Medicines List in South Africa. South African Medical Journal, 105(5).
- Gray, A., & Riddin, J. (2018). The Regulatory System for Medicines in South Africa. Journal of Pharmaceutical Policy and Practice. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300068/
- MSF Access Campaign (2020). Fix the Patent Laws Campaign Report.
- Hofman, K., & McGee, S. (2018). Medicine Pricing and Reimbursement in South Africa. Health Policy and Planning, 33(4).
- Stop Stockouts Project (2021). Annual Report on Medicine Stockouts in Public Facilities.